Please login to the form below
Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes
Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech giants dominate?
By 2026, the number of people using digital therapeutics is estimated to increase by 381%, reaching a market size of $28 billion. This makes digital therapeutics the fastest-growing field in digital health.
Digital therapeutics are evidence-based therapeutic interventions, designed to prevent, manage, or treat a variety of medical conditions, ranging from chronic diseases and neurological disorders to tackling challenges such as medication adherence.
The benefits are far-reaching, from optimizing patient outcomes to reducing the economic burden on healthcare systems. However, the real value lies when digital therapeutics are combined with a medicinal asset. This powerful combination uncovers a wealth of untapped opportunities for biopharmaceutical companies to maximize the value of medicinal assets, driving differentiation and increasing access to safe and effective therapies.
To capitalize on this opportunity, the digital therapeutic must support an asset to fulfill an unmet need. However, as tech giants shape this arena and more needs are catered to, it will become difficult to develop digital platforms that increase value for all stakeholders. As a result, early market entry is fundamental.
In this whitepaper, Fishawack Health consultants explore the market landscape and provide strategic recommendations for manufacturers to leverage the power of digital therapeutics to enhance the value of products and portfolios including:
- Digital therapeutics market growth
- Key therapy areas and applications
- Detailed benefits for stakeholders and advice on overcoming adoption hurdles
- Strategic recommendations for developing a digital therapeutics commercialization strategy that crystalizes the value of an asset
Company Details
Fishawack Health
Address:
No. 3 Booths Park
Booths Hall
Chelford Road
Knutsford
Cheshire
WA16 8GS
United Kingdom
Latest content on this profile
- The challenges of reimbursement and innovative pricing for cell and gene therapies
- Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of innovative pricing models, including ensuring the model chosen meets the payer’s needs.
Fishawack Health
- Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes
- Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech giants dominate?
Fishawack Health
- Fishawack Health welcomes Mario Muredda as its new President of Marketing
- Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.
Fishawack Health
- 5 ways we’re enhancing our services to support our clients in 2023
- Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023.
Fishawack Health
- Why it’s time to apply a payer lens to your early pipeline planning
- Value, evidence, and market access experts Jan McKendrick and Andrea Hamlin reveal why applying a payer lens early in the value assessment of pipeline assets is essential for driving commercial success.
Fishawack Health
- The fast-paced future of cell and gene therapies
- In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist teams.
Fishawack Health
